Clinical Trials
531
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (371 trials with phase data)• Click on a phase to view related trials
Endo-SPONGE for Treatment of Anastomotic or Hartmann's Stump Leakages in Lower Pelvic Area
- Conditions
- Anastomotic LeaksHartmanns Stump Leakage
- First Posted Date
- 2025-06-25
- Last Posted Date
- 2025-06-25
- Lead Sponsor
- Boston Scientific Corporation
- Target Recruit Count
- 66
- Registration Number
- NCT07035431
- Locations
- 🇺🇸
Ascension / St. John Hospital and Medical Center, Saint Clair Shores, Michigan, United States
🇺🇸Barnes Jewish Hospital, Saint Louis, Missouri, United States
🇺🇸Mount Sinai, New York, New York, United States
Randomized Study on Transoral Outlet Reduction and Lifestyle Changes for Weight Regain After Gastric Bypass
- Conditions
- Weight RegainWeight Loss
- First Posted Date
- 2025-06-11
- Last Posted Date
- 2025-06-11
- Lead Sponsor
- Boston Scientific Corporation
- Target Recruit Count
- 108
- Registration Number
- NCT07015424
- Locations
- 🇺🇸
University of South Florida, Tampa, Florida, United States
Stone and Laser Therapies Post-Market Study (SALT)
- Conditions
- Benign Prostate Hypertrophy(BPH)Renal CalculiUreteral Stones, Kidney StonesUrinary Tract ProcedureCalculi, Urinary
- First Posted Date
- 2025-05-21
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Boston Scientific Corporation
- Target Recruit Count
- 238
- Registration Number
- NCT06982235
ACURATE Enhance Post Market Study
- Conditions
- Aortic Valve StenosisAortic Valve CalcificationAortic Diseases
- First Posted Date
- 2025-05-07
- Last Posted Date
- 2025-06-24
- Lead Sponsor
- Boston Scientific Corporation
- Target Recruit Count
- 150
- Registration Number
- NCT06959862
AGENT DCB STANCE: Safety and Effectiveness Study of AGENT Drug-Coated Balloon Compared to Standard of Care Percutaneous Coronary Intervention (PCI) Treatment for de Novo Coronary Lesions
- Conditions
- Coronary Arterial Disease (CAD)de Novo Lesions in Native Coronary Arteries
- First Posted Date
- 2025-05-06
- Last Posted Date
- 2025-07-03
- Lead Sponsor
- Boston Scientific Corporation
- Target Recruit Count
- 1328
- Registration Number
- NCT06959524
- Prev
- 1
- 2
- 3
- 4
- 5
- 101
- Next
News
VIVA24: Late-Breaking Trials Highlight Advances in Vascular Intervention
The PROMISE II trial demonstrates sustained limb salvage and wound healing at 2 years using the LimFlow System for no-option CLTI patients.
VIVA24: Late-Breaking Trials Highlight Advances in Peripheral Artery Disease Treatment
The PROMISE II trial demonstrates sustained limb salvage and wound healing at two years using the LimFlow System for no-option CLTI patients.
VIVA24: Novel Therapies Show Promise in Vascular Disease Treatment
• The Esprit BTK scaffold demonstrated superior long-term outcomes in treating chronic limb-threatening ischemia compared to percutaneous transluminal angioplasty. • Shockwave Javelin Peripheral IVL catheter met efficacy and safety goals, significantly reducing stenosis in severely calcified lesions. • TCAR using the ENROUTE system proves safe and effective for carotid stenosis in standard-surgical-risk patients, with low stroke and cranial nerve injury rates.
Senseonics' Eversense 365 CGM System Receives FDA Clearance for One-Year Use
Senseonics and Ascensia Diabetes Care secured FDA clearance for Eversense 365, a next-generation continuous glucose monitoring (CGM) system, for adults with type 1 and type 2 diabetes.